UK-based AstraZeneca’s acquired rare disease drug has met the primary endpoint in a Phase III trial in patients with chronic ...

A phase 3 trial of AstraZeneca’s $800 million rare disease candidate has met its primary endpoint. The update keeps ...

Angle updates on AstraZeneca development work and Eisai’s phase 2 pilot study: London Tuesday, March 25, 2025, 11:00 Hrs [IST] Angle Inc, a world-leading liquid biopsy company w ...

AstraZeneca's eneboparatide met its Phase 3 trial goal for chronic hypoparathyroidism, while the EU approved Imfinzi for ...

The University of Wisconsin participated in a trial to test AstraZeneca’s COVID-19 vaccine. Though AstraZeneca reported a high efficacy rate, health officials have recently raised concerns about the ...

As AstraZeneca awaits an FDA decision for its Daiichi Sankyo-partnered Datroway in EGFR-mutated non-small cell lung cancer ...

ELRIG, a not-for-profit, volunteer-led organisation for the drug discovery community, today announced the keynote speakers for Therapeutic Oligonucleotides 2025 taking place at the AstraZeneca R&D ...

High-level results from the CALYPSO Phase III trial showed that eneboparatide, AZP-3601, an investigational parathyroid hormone receptor 1 ...

AstraZeneca has built its leading presence ... and Calquence are well positioned based on leading efficacy in hard-to-treat cancers. These drugs also carry strong pricing power to support higher ...

EsoBiotec develops therapies that engineer immune cells within the body, eliminating the need for patients to go through lymphodepletion and reinfusion.

AstraZeneca will acquire all outstanding equity of EsoBiotec for a total consideration of up to $1,000m, on a cash and debt free basis. This will include an initial payment of $425m on deal closing, ...